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Abstract
The biological behavior of melanoma is unfavorable in the elderly when compared to young subjects. We hypothesized 
that differences in T-cell responses might underlie the distinct behavior of melanoma in young and old melanoma patients. 
Therefore, we investigated the circulating T-cell compartment of 34 patients with metastatic melanoma and 42 controls, 
which were classified as either young or old. Absolute numbers of CD4+ T cells were decreased in young and old melanoma 
patients when compared to the age-matched control groups. Percentages of naive and memory CD4+ T cells were not dif-
ferent when comparing old melanoma patients to age-matched controls. Percentages of memory CD4+ T cells tended to be 
increased in young melanoma patients compared to young controls. Proportions of naive CD4+ T cells were lower in young 
patients than in age-matched controls, and actually comparable to those in old patients and controls. This was accompanied 
with increased percentages of memory CD4+ T cells expressing HLA-DR, Ki-67, and PD-1 in young melanoma patients in 
comparison to the age-matched controls, but not in old patients. Proportions of CD45RA−FOXP3high memory regulatory 
T cells were increased in young and old melanoma patients when compared to their age-matched controls, whereas those 
of CD45RA+FOXP3low naive regulatory T cells were similar. We observed no clear modulation of the circulating CD8+ 
T-cell repertoire in melanoma patients. In conclusion, we show that CD4+ T cells of young melanoma patients show signs 
of activation, whereas these signs are less clear in CD4+ T cells of old patients.
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Abbreviations
CTLA-4  Cytotoxic T-lymphocyte-associated protein 4
PBMC  Peripheral blood mononuclear cells
PD-1  Programmed cell death protein 1
TCM cell  CD45RO+CCR7+CD4+ central memory T 
cell
TEM cell  CD45RO+CCR7−CD4+ effector memory T 
cell
TNaive cell  CD45RO−CCR7+CD4+ naive T cell
TTD cell  CD45RO−CCR7−CD4+ terminally differen-
tiated T cell
Introduction
Melanoma is an aggressive form of skin cancer with frequent 
metastases towards other organs. The incidence of melanoma 
in Europe is currently on the rise [1]. Among adolescents and 
young adults, melanoma is the most prevalent type of cancer in 
women and ranks second in men [2]. Nevertheless, melanoma 
is largely a disease of the elderly, as 43% of all newly diag-
nosed patients are 65 years or older. In addition, the median 
age at diagnosis is 64 years for males and 57 for females [3]. 
Importantly, the biological behavior of melanoma differs 
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between young and old patients. Old patients more frequently 
present with unfavorable prognostic tumor factors as evi-
denced by a higher Breslow’s thickness, a higher occurrence 
of histological ulcerative tumors, and a higher mitotic activity 
[4–6]; and, finally, a worse disease-specific survival [6]. Cur-
rently, it is unclear why the biological behavior of melanoma 
differs in young and old patients.
Ample evidence indicates that the immune system plays a 
key role in the outcome of melanoma. Spontaneous regression 
occurs in 3.7–15% of primary melanomas. Even for metastatic 
melanoma, one in every 400 patients reaches a spontaneous 
complete remission [7]. Immune checkpoint inhibitors like the 
anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) 
antibody ipilimumab and the anti-programmed cell death pro-
tein 1 (PD-1) antibodies nivolumab and pembrolizumab have 
demonstrated remarkable efficacy in boosting T-cell responses 
against metastatic melanoma [8]. For the combination of ipili-
mumab and nivolumab, a response rate as high as nearly 60% 
was reported in 2015 [9]. Currently, no validated biomarkers 
are commonly used to select melanoma patients for treatment 
with checkpoint inhibitors.
Aging of the immune system might be a factor contribut-
ing to the unfavorable behavior of melanoma in the elderly. 
Both the innate and adaptive immune arms of the immune 
system are affected by aging [10, 11]. These changes have been 
linked to the increased susceptibility for infections and various 
types of cancer in the elderly [12–14]. T-cell responses might 
be compromised in the elderly due to various perturbations, 
such as reduced numbers and diversity of naïve T cells, skew-
ing of the memory T-cell receptor repertoire, poor cytokine 
secretion, and functional exhaustion of the memory compart-
ment [10, 11, 15–18]. Moreover, numbers of regulatory T 
cells increase with aging. Regulatory T cells inhibit immune 
responses and are essential for preventing autoimmunity. In the 
context of cancer, however, these cells may dampen anti-tumor 
responses. It might, therefore, be possible that aging of cellular 
immunity underlies the unfavorable behavior of melanoma in 
the elderly.
In the current study, we, therefore, investigated the circulat-
ing T-cell compartments of young and old melanoma patients. 
For comparison, we recruited a cohort of aged-matched 
healthy controls. A comprehensive analysis of activation, pro-
liferation, and differentiation markers, checkpoint molecules, 
and regulatory T-cell transcription factors shows that CD4+ T 
cells of young melanoma patients show signs of an ongoing 
immune response, whereas these signs are lacking in CD4+ T 
cells of old melanoma patients.
Materials and methods
Study subjects
Peripheral blood was obtained from 34 systemic treatment-
naive, metastatic melanoma patients, who were either clas-
sified as ‘young’ when ≤ 50 years of age (n = 11) or ‘old’ 
when ≥ 65 years of age (n = 18). For three patients, only 
lymphocyte true count could be performed due to logistic 
reasons. In addition, blood samples were obtained from 42 
age-matched healthy controls that were young (n = 13) or 
old (n = 39). Health of the control subjects was assessed by 
health assessment questionnaires, physical examination, 
and blood tests as previously described [11]. Melanoma 
patients using immune-modulating drugs or having infec-
tions, other types of malignant disease, or autoimmune 
disease were excluded from the study.
Flow cytometry
Peripheral blood mononuclear cells (PBMC) were isolated 
by density centrifugation with Lymphoprep (Axis-Shield). 
PBMC or whole blood samples were stained with the fol-
lowing fluorochrome-conjugated monoclonal antibodies: 
CD3-efluor605, CD4-efluor450, CD27-APC-efluor780, 
HLA-DR-efluor780, CD45RA-efluor605, FOXP3-PE (eBio-
science), CD4-APC-H7, CD8-Percp, CD8-PE-Cy7, CD31-
AF647, CD45RO-FITC, CD45RO-PE-Cy7, CCR7-PE-Cy7, 
Ki-67-Percp-cy5.5, CTLA-4-BV421 (BD Biosciences), PD-
1-PE, CD28-AF700 (Biolegend), and CD161-PE (Miltenyi 
Biotec). Intracellular staining for FOXP3, Helios, Ki-67, 
and CTLA-4 was performed after cells were permeabilized 
with a FOXP3 staining buffer set according to instructions 
of the manufacturer (eBioscience). Whole blood samples 
were treated with BD lysing solution according to the 
instructions of the manufacturer (BD Biosciences). Stained 
samples were analyzed on a LSR-II flow cytometer (BD 
Biosciences). Analysis was performed with Kaluza Flow 
Analysis Software (Beckman Coulter). Absolute numbers of 
CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells, and NK 
cells were determined according to the MultiTest TruCount 
method (BD Biosciences), as described by the manufacturer. 
TruCount samples were measured on a FACSCanto-II (BD 
Biosciences) and analyzed with FACSCanto Clinical Soft-
ware (BD Biosciences).
Statistics
Demographics and baseline characteristics of all patients 
were summarized using descriptive statistics. The Mann 
Cancer Immunology, Immunotherapy 
1 3
Whitney U Test was used to compare different groups. 
Analyses were performed with GraphPad Prism 5.0. Two-
tailed p values < 0.05 were considered significant.
Results
Subjects characteristics and lymphocyte numbers
Baseline characteristics of the melanoma patients and 
healthy controls are shown in supplemental Table 1 and 
supplemental Table  2, respectively. The time between 
development of metastases after discovery of the primary 
tumor was shorter in old compared to young melanoma 
patients, albeit not statistically significant. Markers of sys-
temic inflammation—erythrocyte sedimentation rate and 
C-reactive protein—tended to be higher in young patients 
than in old patients. Absolute numbers of CD3+ T cells were 
lower in melanoma patients when compared to their aged-
matched healthy controls (Table 1). This difference could be 
explained by a numerical decline of CD4+ T cells in mela-
noma patients, whereas numbers of circulating CD8+ T cells 
were similar in patients and controls. Absolute numbers of 
B cells were decreased in young and old melanoma patients 
compared to the aged-matched control. Numbers of NK cells 
were similar in patients and controls. Thus, absolute num-
bers of circulating CD4+ T cells and B cells are altered in 
patients with metastatic melanoma.
For melanoma patients, subsequent treatment after inclu-
sion and survival outcomes are provided in supplemental 
Table 3.
T‑cell differentiation subsets
We investigated if the lower number of CD4+  T 
cells in melanoma patients resulted from a decline 
of particular T-cell differentiation subsets. There-
fore, we further divided the CD4+  T cells com-
par tment into CD45RO−CCR7+  naive  (TNaive) , 
C D 4 5 RO + C C R 7 +   c e n t r a l  m e m o r y   ( T C M) , 
CD45RO+CCR7− effector memory  (TEM),  and 
CD45RO−CCR7− terminally differentiated  (TTD) 
cells (Fig. 1a). Proportions of CD4+ TNaive cells were 
decreased in young melanoma patients when compared 
to age-matched healthy controls (Fig. 1b). Proportions 
of CD4+ TNaive cells in young melanoma patients were 
actually similar to those in old patients and controls. We 
observed trends for increased proportions of CD4+  TCM 
and  TEM cells in young melanoma patients versus age-
matched controls (Fig.  1c, d), whereas proportions of 
CD4  TTD cells were similar in young patients and con-
trols (Fig. 1e). The percentages of all CD4+ T-cell dif-
ferentiation subsets were similar in old melanoma patients 
and age-matched controls. We obtained similar results 
when CD4+ TNaive and CD4+  TTD cells were more strin-
gently defined as CD45RO−CCR7+CD27+CD28+ and 
CD45RO−CCR7−CD27−CD28− cells, respectively (Sup-
plemental Fig. 1). Although percentages of CD8+ TNaive 
cells tended to be somewhat lower in young melanoma 
patients versus young healthy controls, we observed no 
clear differences between CD8+ T-cell differentiation 
subsets of melanoma patients and healthy controls (Sup-
plemental Figs. 2a, 2b, 2c and 2d).
As CD4+ TNaive cells were found reduced in young 
melanoma patients, we next determined if CD31+ thymic 
emigrant CD4+ TNaive cells or post-thymically expanded 
CD31− central CD4+ TNaive cells were decreased in young 
melanoma patients (Fig. 1f). Proportions of CD31+ thymic 
emigrant CD4+  TNaive cells were decreased in young 
patients when compared to age-matched controls (Fig. 1g). 
Young melanoma patients were actually demonstrating 
similar low proportions of these cells, as old patients 
and controls. In contrast, proportions of post-thymically 
expanded CD31– central CD4+ TNaive cells were com-
parable in young and old melanoma patients versus the 
age-matched controls (Fig. 1h). Thus, the CD4+ TNaive 
cell compartment of young melanoma patients resembled 
Table 1  True counts of 
peripheral lymphocyte subsets 
shown for young and old 
metastatic melanoma patients 
compared to age-matched 
healthy controls
HC healthy controls, NK natural killer
*p < 0.05 or **p < 0.01
a p value: 0.057
b p value: 0.051
Young HC (n = 13) Young melanoma 
patient (n = 13)
Old HC (n = 28) Old melanoma 
patients (n = 18)
CD3+ count, × 109/L 1.12 (0.78–1.59) 0.89 (0.47–1.59)* 1.28 (0.55–2.34) 0.93 (0.50–2.28)*
CD4+ count, × 109/L 0.79 (0.18–0.99) 0.51 (0.24–0.95)a 0.89 (0.33–1.43) 0.53 (0.31–1.21)**
CD8+ count, × 109/L 0.32 (0.19–0.74) 0.30 (0.10–0.57) 0.34 (0.10–1.25) 0.24 (0.06–1.00)
B cell counts,× 109/L 0.19 (0.08–0.50) 0.12 (0.03–0.22)* 0.18 (0.06–0.50) 0.13 (0.04–4.19)b
NK cell counts, × 109/L 0.15 (0.06–0.44) 0.19 (0.06–0.37) 0.31 (0.07–0.65) 0.21 (0.03–0.51)
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those of old patients and controls, rather than that of young 
healthy controls.
Expression of activation and proliferation markers 
by circulating CD4+ T cells
We studied the activation status of CD4+  T cells in 
the young and old melanoma patients by determining 
the percentage of HLA-DR expressing cells (Fig. 2a). 
Percentages of HLA-DR expressing cells were increased 
among CD4+ T cells of young melanoma patients when 
compared to those in young controls. Proportions of HLA-
DR expressing CD4+ T cells in young melanoma patients 
resembled those in old patients and controls.
In addition, we determined the percentage of proliferat-
ing CD4+ T cells by analyzing these cells for expression of 
Ki-67 (Fig. 2b). The percentage of Ki-67 expressing cells 
was higher in CD4+ T cells of young melanoma patients 
Fig. 1  CD4+  T-cell differentiation subsets in melanoma patients 
and controls. a Representative flow cytometric staining of CD45RO 
and CCR7 in CD4+ T cells in melanoma patients and age-matched 
controls. Percentages of b CD45RO−CCR7+CD4+  TNaive cells, c 
CD45RO+CCR7+CD4+  TCM cells, d CD45RO+CCR7−CD4+ TEM, 
and e CD45RO−CCR7−CD4+ TTD cells in young controls (n = 13), 
young patients (n = 11), old controls (n = 39), and old patients 
(n = 15). f Representative flow cytometric staining for CD31 in 
CD4+ T cells in melanoma patients and healthy controls. Percentages 
of g CD31+ thymic emigrant CD4+ TNaive cells and h CD31− central 
CD4+  TNaive cells in the same patients and controls. Statistical sig-
nificance is indicated as *p < 0.05, **p < 0.01 and ***p < 0.001
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than those of age-matched healthy controls. In contrast, no 
modulation of Ki-67 was observed in CD4+ T cells of old 
melanoma patients when compared to their age-matched 
controls. No substantial increase of Ki-67 expression was 
observed among CD8+ T cells of melanoma patients, 
although the percentage of Ki-67 expressing cells tended to 
be slightly increased among CD8+ T cells of old melanoma 
patients versus old healthy controls (Supplemental Fig. 2e).
We also assessed CD4+ T cells for expression of CD161 
(Fig. 2c), a killer cell lectin-like receptor that identifies a 
population of highly pro-inflammatory cells capable of pro-
ducing interferon-γ and tumor necrosis factor-α [19]. Young 
melanoma patients showed an increase of CD161 expressing 
Fig. 2  Activation and prolif-
eration of CD4+ T cells in 
melanoma patients and controls. 
a Left panel: representa-
tive staining of HLA-DR on 
CD4+ T cells of patients and 
controls. Right panel: percent-
ages of HLA-DR4+CD4+ T 
cells in young controls (n = 12), 
young patients (n = 10), old 
controls (n = 34), and old 
patients (n = 15). b Left panel: 
representative staining of 
intracellular Ki-67 in CD4+ T 
cells of patients and controls. 
Right panel: percentages of 
Ki-67+CD4+ T cells in young 
controls (n = 10), young patients 
(n = 10), old controls (n = 10), 
and old patients (n = 10). c Left 
panel: representative stain-
ing of CD161 on CD4+ T 
cells of patients and controls. 
Right panel: percentages of 
CD161+CD4+ T cells in young 
controls (n = 13), young patients 
(n = 11), old controls (n = 39), 
and old patients (n = 15). Sta-
tistical significance is indicated 
as *p < 0.05, **p < 0.01, and 
***p < 0.001
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CD4+ T cells compared to young controls. In contrast, the 
percentage of CD161 expressing cells was similar in old 
melanoma patients and age-matched controls. In addition, 
percentages of CD161 expressing CD8+ T cells were simi-
lar in melanoma patients, irrespective of age (Supplemental 
Fig. 2f). Thus, circulating CD4+ T cells of young melanoma 
patients show clear signs of an ongoing immune response, 
whereas these signs are lacking in CD4+ T cells of old mela-
noma patients.
PD‑1 and CTLA‑4 expression by CD4+ T cells
We determined if CD4+ T cells of young and old mela-
noma patients show increased expression of the check-
point molecules PD-1 and CTLA-4. Percentages of PD-1 
expressing cells were increased in young melanoma 
patients when compared to age-matched controls (Fig. 3a). 
In contrast, the percentage of PD-1 expressing CD4+ T 
cells was not modulated in old melanoma patients. The 
percentage of CTLA-4 expressing cells CD4+ T cells was 
similar in melanoma patients and controls, both in young 
subjects and old subjects (Fig. 3b). Percentages of PD-1 
and CTLA-4 expressing CD8+ T cells were comparable 
in melanoma patients and healthy controls, irrespective of 
age (Supplemental Figs. 2g and 2 h). Taken together, the 
CD4+ T-cell compartment of young melanoma patients, 
but not old melanoma patients, shows increased expression 
of the checkpoint inhibitor PD-1 but not CTLA-4.
Regulatory T cells
Finally, we questioned if numbers of regulatory T cells are 
modulated in melanoma patients. Therefore, we assessed 
the proportions of CD45RA+FOXP3low naive regulatory T 
cells and CD45RA−FOXP3high memory regulatory T cells 
in the peripheral CD4+ T-cell compartment of patients 
and controls (Fig.  4a). The proportions of CD45RA+ 
 FOXP3low naive regulatory T cells were, irrespective of 
age, comparable in melanoma patients and healthy con-
trols (Fig. 4b). In contrast, we observed a clear increase of 
CD45RA-FOXP3high memory regulatory T cells in young 
and old melanoma patients when compared to their age-
matched controls (Fig. 4c). Thus, we observed preferential 
Fig. 3  Expression of checkpoint 
molecules by CD4+ T cells of 
melanoma patients and controls. 
a Left panel: representative 
staining for PD-1 on CD4+ T 
cells of patients and controls. 
Right panel: percentages of 
PD-1+CD4+ T cells in young 
controls (n = 10), young patients 
(n = 10), old controls (n = 10), 
and old patients (n = 10). b Left 
panel: representative staining 
of intracellular CTLA-4 in 
CD4+ T cells of patients and 
controls. Right panel: percent-
ages of CTLA-4+CD4+ T cells 
in the same donors as men-
tioned in a. Statistical signifi-
cance is indicated as **p < 0.01
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expansion of CD45RA−FOXP3high memory regulatory T 
cells in patients with metastatic melanoma.
Discussion
Our findings indicate a temperate CD4+ T-cell response 
in the peripheral blood of old melanoma patients, whereas 
CD4+ T cells of young melanoma patients showed promi-
nent signs of activation, proliferation, and differentiation. 
The notion of an ongoing immune response in young mela-
noma patients is further substantiated by the decrease of 
thymic emigrant CD4+  TNaive cells and the concomitant 
expansion of  TCM and inflammatory  TEM when compared 
to age-matched controls. Interestingly, proportions of 
CD4+  TNaive cells in young melanoma patients were com-
parable to those in the old patients and controls, suggest-
ing a melanoma-induced immune response. Thus, our find-
ings suggest poor activation of peripheral CD4+ T cells in 
old melanoma patients, whereas the CD4+  TNaive cell pool 
shows signs of premature contraction in young melanoma 
patients. The latter finding may be due to chronic stimula-
tion with melanoma antigens.
The reduced activation status of circulating CD4+ T 
cells in old melanoma patients might contribute to the 
worse biological behavior and survival of melanoma in 
the elderly [6]. CD4+ T cells play a central role in anti-
tumor responses and empower tumor-specific CD8+ T 
cells to gain their full cytotoxic phenotype. It remains to 
be elucidated why CD4+ T cells respond poorly to mela-
noma in the elderly. Both CD4+ T-cell inherent changes 
and functional impairment of antigen presenting cells are 
likely relevant. Remarkably, therapeutic melanoma trials 
with checkpoint inhibitors directed to CTLA-4 or PD-1 
that prospectively stratify patients for age to assess for dif-
ferences in outcome report that the response is independ-
ent of age [20–23]. One explanation for the latter finding 
might be the substantial selection bias in these therapeutic 
studies towards fit elderly with a more indolent disease 
course.
Although the CD4+ T cells of young melanoma patients 
showed clear signs of activation and proliferation, these 
subjects all had metastatic disease. This means that their 
immune system has failed to prevent disease progression 
and the degree of activation is, therefore, proven to be 
insufficient. Remarkably, we observed low proportions of 
CD4+  TNaive cells in young melanoma patients in com-
parison to age-matched controls. The proportions of these 
cells were actually comparable to those in old patients 
and controls. Interestingly, this premature contraction of 
the CD4+  TNaive cell pool in young melanoma patients 
could be entirely attributed to a decrease of CD31+ thymic 
emigrant CD4+  TNaive cells. Although it is unclear if this 
premature contraction has developed due to or prior to dis-
ease, it likely compromises CD4+ T-cell immunity against 
the full spectrum of melanoma antigens.
We observed increased expression of PD-1 on circu-
lating CD4+ T cells in young melanoma patients. This 
is an interesting finding, as PD-1 blocking therapy has 
proven successful in melanoma patients [21, 22]. PD-1 is 
an inhibitory receptor expressed by memory T cells and 
an early marker of exhausted T cells [24]. The increased 
expression of PD-1 on CD4+ T cells in young patients 
likely mirrors the activation of these cells. In contrast, 
we observed no clear modulation of CTLA-4 in CD4+ T 
cells of melanoma patients and healthy controls. Baseline 
signatures of peripheral blood biomarkers are studied to 
predict response to immune checkpoint inhibitors [25]. 
Fig. 4  Regulatory T-cell frequencies in melanoma patients and 
controls. a Representative staining for intracellular FOXP3 and 
CD45RA in CD4+ T cells of patients and controls. Percentages of b 
CD45RA+FOXP3low naive regulatory T cells and c CD45RA−FOX-
P3high memory regulatory T cells in young controls (n = 10), young 
patients (n = 10), old controls (n = 10), and old patients (n = 10). Sta-
tistical significance is indicated as *p < 0.05
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For example, decreasing levels of CD4+CD25+FOXP3+ 
regulatory T cells during ipilimumab therapy are associ-
ated with a favorable response [26]. Whether peripheral 
baseline PD-1 or CTLA-4 expression levels are useful to 
incorporate in a predictive biomarker signature is currently 
unclear.
Proportions of memory regulatory T cells were 
increased in both young and old melanoma patients. Previ-
ously, CD45RA+  FOXP3low naive regulatory T cells and 
CD45RA−FOXP3high memory regulatory T cells have 
been identified in the circulation of humans [27]. These 
two regulatory T-cell populations should be discriminated 
from CD45RA−FOXP3low effector T cells, which lack sup-
pressive functions. We here show that proportions of naive 
regulatory T cells are unaltered in melanoma patients. In 
contrast, proportions of memory regulatory T cells were 
increased in the circulation of young and old melanoma 
patients. It has been shown that memory regulatory T cells 
are immune-capable of migrating towards non-lymphoid tis-
sues, including the skin [28]. Therefore, the expansion of 
memory regulatory T cells might be an unfavorable event 
in melanoma patients.
We are aware that our findings do not necessarily reflect 
immune responses at the tumor site in melanoma patients. 
Brisk tumor-infiltrating lymphocytes and high lymphocyte 
tumor distribution and density in melanoma are associated 
with improved disease-specific survival [29]. A study with 
tumor tissue samples from 147 metastatic melanoma patients 
showed an independent positive association between over-
all survival and higher counts of CD8+ T cells and PD-1 
expressing cells [30]. CD4+ T-cell and regulatory T-cell 
counts were not predictive of survival. However, these cells 
may primarily fulfill their functions outside the tumor site, 
for instance in surrounding secondary or tertiary lymphoid 
structures. It would, therefore, be interesting to study CD4+ 
T cells in lymphoid tissues of melanoma patients.
In conclusion, our findings indicate that circulating CD4+ 
T cells in young patients with metastatic melanoma are quite 
strongly activated, whereas CD4+ T cells of old melanoma 
patients seem relatively dormant. This difference might con-
tribute to unfavorable behavior of melanoma in the elderly. 
In addition, our findings suggest premature contraction of 
the CD4+  TNaive cell compartment in young patients with 
metastatic melanoma.
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